Official account for the journal of Human Genomics
- Tweets195
- Following644
- Followers209
- Likes215
ALT Table: Projected COVID-19-Attributable Deaths, Hospitalizations, Infections, and Direct Medical Costs Averted by the U.S. Booster Vaccination Program Under Two Potential Scenarios Between August 1, 2022, and March 31, 2023 Baseline Scenario: Vaccinations Continue at Current Daily Rate Through March 31, 2023 Vaccination campaign scenario 1: COVID booster vaccination coverage of eligible population equal to 2020–2021 influenza vaccination levels by October 31, 2022 Deaths averted: 101,858 Hospitalizations averted: 1,028,389 Infections averted: 24,958,716 Direct medical costs averted: $62,612,070,303 Vaccination campaign scenario 2: 80% of those who are eligible to receive their first or second COVID booster doses are vaccinated by October 31, 2022 Deaths averted: 159,827 Hospitalizations averted: 1,738,188 Infections averted: 48,369,111 Direct medical costs averted: $109,474,464,016
![The post-arrival transmission for pre-arrival testing. Specifying an incubation period of 3.1 days, an RT-PCR diagnostic sensitivity based on data from Hellewell et al [24], and 35.1% infections as asymptomatic throughout disease, we calculated (A) the reduction in the post-arrival transmission compared to no pre-departure testing and (B) the probability of post-arrival transmission for a basic reproduction number of 6.93 when there is no pre-departure testing (gray dotted line), or when there is pre-departure testing using an RT-PCR test (black solid line), the BD Veritor (purple dashed line), BinaxNOW (red dashed line), CareStart (blue dashed line), LumiraDx (yellow dashed line), and Sofia (green dashed line) rapid antigen test conducted at departure or any previous day, up to 7 days prior to departure (United States, 2021–2022).](https://pbs.twimg.com/media/FYsMQCIWAAAn1ha.jpg?name=orig)
ALT The post-arrival transmission for pre-arrival testing. Specifying an incubation period of 3.1 days, an RT-PCR diagnostic sensitivity based on data from Hellewell et al [24], and 35.1% infections as asymptomatic throughout disease, we calculated (A) the reduction in the post-arrival transmission compared to no pre-departure testing and (B) the probability of post-arrival transmission for a basic reproduction number of 6.93 when there is no pre-departure testing (gray dotted line), or when there is pre-departure testing using an RT-PCR test (black solid line), the BD Veritor (purple dashed line), BinaxNOW (red dashed line), CareStart (blue dashed line), LumiraDx (yellow dashed line), and Sofia (green dashed line) rapid antigen test conducted at departure or any previous day, up to 7 days prior to departure (United States, 2021–2022).
ALT Monkeypox update flyer Thursday, June 9 2-3pm EST